

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 25 avril 2023 13:33

Laboratory Information

Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	
Address of laboratory:	
Tel.:	
E-mail address:	
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	
Name (including Title and Position) of WOA Reference Expert:	
Which of the following defines your laboratory? Check all that apply:	

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CFT	Yes	4848	1898
ELISA	Yes	0	2
Direct diagnostic tests		Nationally	Internationally
Culture	Yes	0	8
PCR	Yes	0	8

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOA?H MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Burkholderia mallei DNA	PCR	Provided		30.24 MG	1	Asia and Pacific
Burkholderia pseudomallei DNA	PCR	Provided		10.08 MG	1	Asia and Pacific
Negative serum control	CFT/ELISA	Provided		10 ML	1	Asia and Pacific
Positive serum control	CFT/ELISA	Provided		15 ML		Asia and Pacific

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA?H Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA?H Members?

Yes

NAME OF WOA?H MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES

BAHRAIN	2022-01-01	CFT	605	0
BRAZIL	2022-01-01	CFT	21	0
EGYPT	2022-01-01	CFT	106	0
ESTONIA	2022-01-01	CFT	6	0
JORDAN	2022-01-01	CFT	210	0
KUWAIT	2022-01-01	CFT	201	0
OMAN	2022-01-01	CFT	201	0
SAUDI ARABIA	2022-01-01	CFT	548	0

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHP Member?

Yes

NAME OF THE WOAHP MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
BRAZIL	Disease control and serological confirmation	E-mail
SAUDI ARABIA	Serological result interpretation and serological test confirmation	E-mail
SINGAPORE	Diagnostic test establishment	E-mail

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAHP MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
To determine antigen working dilution for Glanders CFT	1 year	To produce reference control sera	Anses, France	FRANCE

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Monitoring disease situation in this region by performing serological investigations on equine sera sent from neighboring countries.

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

All data produced at CVRL are sent to the authorities at the Ministerial level of the UAE and the home countries from where we received the samples.

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1

Appelt, S., A.M. Rohleder, D. Jacob, H. von Buttlar, E. Georgi, K. Mueller, U. Wernery, J. Kinne, M. Joseph, S. V. Jose and H.C. Scholz (2022) Genetic diversity and spatial distribution of *Burkholderia mallei*. PLOS Neglected Tropical Diseases. 17(7), e0270499.
<https://doi.org/10.1371/journal.pone.0270499>

b) International conferences:

0

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

0

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
17025:2017	pdf	CentralVeterinaryLaboratory-CVRL-LB-TEST-208(004)Certificate2022.pdf
17025:2017	pdf	MBG_LAB_078_LB_MED_Human.pdf
17025:2017	pdf	MBG_LAB_138-LB_TEST_Vet_(1).pdf
17025:2017	pdf	iasc.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
AHS	IAS, USA
Equine Piroplasmiasis	IAS, USA
Equine Infectious Anaemia	IAS, USA
Equine Viral Arteritis	IAS, USA
Glanders	IAS, USA
Dourine	IAS, USA
CEM	IAS, USA
Brucellosis	IAS, USA
West Nile	IAS, USA
Strangles	IAS, USA
EHV 1& 4	IAS, USA
Influenza A virus isolation	IAS, USA
Avian Paramyxovirus Type- 1 virus isolation	IAS, USA
MERS CoV	IAS, USA
ELISA techniques for various diseases	IAS, USA
CFT techniques for various diseases	IAS, USA
AGID technique for various disease	IAS, USA

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory facility, management practices, and biosecurity procedures are regularly monitored to ensure specific biosafety and laboratory biosecurity at CVRL.

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

No

TOR10: NETWORK WITH WOA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOA REF. LABS/ ORGANISING WOA REF. LAB.
Validation of reagents used for CFT.	Participant	5	Anses, France

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOA REF. LABS/ ORGANISING WOA REF. LAB.
Validation of reagents used for CFT.	Participant	10	Anses, France

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

TITLE OF THE PROJECT OR CONTRACT	SCOPE	NAME(S) OF RELEVANT WOA REFERENCE LABORATORIES
Test result confirmation	Disease diagnosis	FLI, Germany
Reagent standardization for CFT, inter-lab comparison study	CFT control sera validation	Anses, France

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen?

No

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?

Yes

KIND OF CONSULTANCY	Location	SUBJECT (FACULTATIVE)
e-mail	France	WOAH-Terrestrial manual chapter review

29. Additional comments regarding your report:

No